Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06214923 · ClinicalTrials.gov registry record · NA

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)

A NA study of Pain and Virtual Reality, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
NA
Development phase
78
Enrollment target
2
Study locations

NCT06214923: Recruiting NA study of Pain and Virtual Reality, sponsored by University of Maryland, Baltimore.

NCT06214923 is a NA study of Pain and Virtual Reality that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 78 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06214923, a NA study of Pain and Virtual Reality, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
NA
Development phase
78 participants
Enrollment target
2
Study locations

Study Summary

This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.

Primary Outcome

EEG response PAF when participants are undergoing the in-person VR

Interventions

  • DEVICE RelieVRx
  • DEVICE Sham-VR
  • OTHER No-VR (natural history control)

Study Locations (2)

Maryland

  • Luana Colloca - Baltimore
  • University of Maryland - Baltimore

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2024-04-09
Est. Completion 2026-11-30
Phase NA
University of Maryland, Baltimore

560 total trials

What NCT06214923 shows while recruiting

NCT06214923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower).

The record links to 4 conditions, with Pain appearing as the primary indexed condition, and to 3 interventions - of which RelieVRx is the first listed.

NCT06214923 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06214923 about?

NCT06214923 is a clinical study titled "Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)". This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.

What is the current status of trial NCT06214923?

This trial is currently recruiting. It is a NA study. The enrollment target is 78 participants. The study started on 2024-04-09. Estimated completion is 2026-11-30.

What conditions does trial NCT06214923 study?

This clinical trial studies the following conditions: Pain, Virtual Reality, Placebo, Temporomandibular Disorder.

What interventions are being tested in trial NCT06214923?

The interventions under investigation include: RelieVRx (DEVICE), Sham-VR (DEVICE), No-VR (natural history control) (OTHER).

Who is sponsoring clinical trial NCT06214923?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06214923 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06214923's enrollment target sits among peer trials

78 206th of 374 higher than 169 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02397668 · 78 participants · NA

    CorMatrix Cor TRICUSPID ECM Valve Replacement Study

  • NCT03321656 · 78 participants · Phase 2

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

  • NCT03687814 · 78 participants · NA

    Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

  • NCT04018872 · 78 participants · Phase 2

    Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06214923, the US trial registry maintained by the National Library of Medicine. NCT06214923 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.